In hepatology, non-invasive biomarkers are redefining how liver diseases like NAFLD, NASH, and hepatitis are diagnosed and monitored. From serum markers and elastography to genomic profiling, these techniques reduce the need for liver biopsies and enable early detection.
 

At Gastro 2025, leading hepatologists will showcase breakthroughs in biomarker validation, discuss clinical adoption strategies, and share data on how these tools impact liver transplant decision-making.
 

For practitioners looking to stay at the forefront, this is a prime opportunity. Be sure to view the full program, or if you have a research project to share, submit an abstract. Don’t miss the chance — register today.